BioSpace News Archive

Endo International plc (NASDAQ: ENDP) today announced that it received U.S. Food and Drug Administration (FDA) approval of Qwo™ (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women.

Masimo announced the results of a study published in Pneumonia in which independent researchers in New Delhi, India, investigated the accuracy of Masimo RRp® on pediatric patients with the Rad-G™ Pulse Oximeter by comparing it to clinician-determined values while performing routine assessment of children admitted to outpatient and emergency departments.

GenSight Biologics, a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, reported that Leber Hereditary Optical Neuropathy subjects treated with LUMEVOQ® experienced sustained efficacy and safety three years after a single injection with the gene therapy.

Medivir AB announced that it has entered a research collaboration with the Drug Discovery and Development Platform at SciLifeLab on potential inhibitors of SARS CoV-2.

Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization, announces Yuk Chun Chiu as Vice President of Manufacturing Operations.

SINOMED, a developer of innovative neuro- and cardiovascular technologies, announced the completion of the 1-year follow-up in the PIONEER-III, randomized global trial evaluating the BuMA Supreme Drug-Eluting Coronary Stent.

Cyxone, a Swedish biotech in autoimmune diseases, announces that the company has engaged Dr Maarten Kraan as Senior Scientific Advisor for the company’s project for Rabeximod in rheumatoid arthritis.

Myomo, Inc. announced that new published research measuring the benefits of the Company’s MyoPro myoelectric orthosis found “Despite long-standing traumatic brain injury, meaningful improvements in motor function were observed.”

MiMedx Group, Inc., an industry leader in advanced wound care and an emerging therapeutic biologics company, announced the filing of its 2019 Annual Report.

MiMedx Group, Inc., an industry leader in advanced wound care and an emerging therapeutic biologics company, announced the filing of its 2020 first quarter Form 10-Q.